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Identity 
 
Numerous cutaneous neurofibromas (A.) and a large plexiform neurofibroma (B.). 
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Classification 
Neurofibromas are benign tumors of the peripheral 
nerves. 
Dermal neurofibromas are well circumscribed solid 
cutaneous tumors with limited size. 
Plexiform neurofibromas (PNF) originate from 
subcutaneous or visceral peripheral nerves and involve 
multiple fascicles extending along the length of a 
nerve. 
In contrast to dermal neurofibromas, plexiform 
neurofibromas vary in size and can be extremely large. 
Multiple dermal neurofibromas are the hallmark of 
neurofibromatosis type 1 (NF1), an autosomal 
dominant genetic disease with an incidence of 
approximately 1 in 3000. Plexiform neurofibromas 
develop in approximately 30% of NF1 patients. While 
dermal neurofibromas also occur in non-NF1 patients, 
PNFs are almost exclusively associated with NF1. 
Clinics and pathology 
Disease 
Neurofibromatosis type 1 (NF1) is an autosomal 
genetic disease caused by heterozygous dysfunction of 
the NF1 tumor suppressor gene on the long arm of 
chromosome 17. 
Embryonic origin 
Neurocrest. 
Etiology 
The genetic cause for neurofibromas is the bi-allelic 
inactivation of the NF1 tumor suppressor gene. 
Epidemiology 
Both sexes can be affected. Neurofibromas are rare in 
children, but start develop in puberty. Up to thousands 
of neurofibromas can develop in one adult NF1 patient. 
In contrast to dermal neurofibromas, PNF are often 
congenital and may develop already before birth. 
Clinics 
Neurofibromas are mostly benign. These tumors can 
lead to transient stinging, itching, and pain. Multiplicity 
of these tumors often causes disfigurement with 
psychological impact on the individual's selfesterm, 
partnerships and social relations. 
However, dermal neurofibromas usually do not cause 
any further serious dysfunction. There is no evidence 
for malignant transformation of dermal neurofibromas. 
In contrast, PNF often lead to pain, disfigurement, 
neurological and other clinical deficits. PNF mostly 
show net-like growth pattern along nerve roots 
extending from a main nerve root to a small distal 
branch, and can be divided into two main types: 
internal tumors and superficial ones. 
Superficial PNF do not cross tissue planes and are 
amenable to complete or nearly complete surgical 
resection. 
Internal PNF extend through multiple tissue planes and 
can not be completely removed in most cases without 
damaging tissues and organs. PNF located in the chest, 
abdomen or pelvis are frequently detected as paraspinal 
masses that involves multiple spinal levels. These 
tumors may also appear as anterior mediastinal masses, 
sciatic nerve lesions with pelvic extension, and 
perirectal plexiform and uterine tumors, all leading to 
sever clinical complications. Furthermore, there is a 
risk of malignant progression in PNF, especially the 
internal ones. While dermal neurofibromas mostly 
appear during adolescence, PNF are mainly congenital 
though some of them become apparent later. Growth of 
PNF is slows down with increasing age. 
Pathology 
According to the WHO classification dermal and 
plexiform neurofibromas are grade I tumours. 
Histologically they consist of transformed Schwann 
cells with wavy contours and ovoid to elongated nuclei 
with fine dense heterochromatin. The tumours show a 
diffuse growth or an arrangement of cells in streams. 
The Schwann cells are intermingled with fibroblasts 
and perineurial-like cells in a matrix of muco-
substances and a varying amount of collagen fibres. 
Within the tumour, especially in dermal neurofibromas, 
mast cells and perivascular lymphocytic infiltrates may 
be demonstrated. In some patients focal palisading of 
small groups of nuclei may resemble Meissner 
corpuscles and arrangement of cells in dense whorls 
may resemble Pacini corpuscles. Plexiform tumours 
typically show a low cellularity, loose texture and an 
abundant myxoid matrix. Degenerating nerve fibres 
may be seen within the tumour. There are no signs of 
malignancy and proliferative activity is low or absent in 
both, dermal and plexiform neurofibroma. 
Some cases may show a mixed Schwannoma-
neurofibroma differentiation, these tumours are termed 
'Schwannoma in Neurofibroma'. 
Immunohistochemical labelling of tumour cells with 
antibodies against S-100 protein is particularly helpful 
in tumours with extremely low cellularity like in 
dermal neurofibromas of the mamilla. 
Treatment 
Surgery: Plastic surgeons should be consulted for 
surgical resection of neurofibromas, especially for 
those of face and neck. The result of the surgery 
dipendends on the size, localization, and structure 
(diffuse, nodular, or pendunculated) of the tumors. 
Pendunculated neurofibromas can be excised with a 
very satisfactory result. Various techniques can be 
applied for resection of neurofibromas: conventional 
scalpel, laser or electrocauterization.  
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Labelling of tumour cells in dermal (left) and plexiform neurofibroma (right)with antibodies against S-100 protein. 
 
According to our experience, conventional scalpel is 
suitable for larger, exophytic tumors. Laser and 
electrocauterization are useful for tumors with 
intracutaneous localization with abundent blood 
vessels. There is no proven benefit for carbon dioxide 
laser treatment for neurofibromas. No relapse will 
occur upon completely resection. Anti-histamine is not 
always satisfactory as a treatment for itching of 
neurofibromas. 
Hormones: Hormonal factors seem to contribute to the 
growth of neurofibromas, as neurofibroma growth is 
stimulated by puberty and pregnancy. A recent study 
has shown that 75% of neurofibromas carry 
progesterone receptors. However, there is no evidence 
that progesterone and combined oral contraceptive pill 
stimulate growth of neurofibromas. For pregnant NF1 
patient, obstetrician and clinicians should be aware that 
spinal and pelvic neurofibromas may progress rapidly 
and thus need to be monitored closely. 
Plexiform neurofibromas: Deeply located tumors 
PNF often lead to pain and neurological deficits and 
thus need special attention and closely monitoring. 
Patients developing deficits or pain should undergo 
surgery whenever a positive outcome is suggested. 
Annual examination helps to detect first indication of 
possible spinal cord compression. Regular MRI is 
important for early detection of malignant 
transformation. 
Results of surgery of PNF are usually unsatisfactory 
because of the network-like growth of the tumors often 
involve multiple nerve fascicles and other adjacent 
tissues. Typically surgical interventions for PNF are 
restricted to debulking procedures of large tumors 
causing significant clinical complications or aesthetic 
disfigurement. However, successful subtotal resections 
of the superficial PNF with significant improvement in 
cosmetic appearance are possible. Furthermore, a 
recent study reported the advantage of early surgical 
intervention of small PNF in children under 15 years of 
age. Total resection was achieved in all 7 cases without 
causing any neurological or organic deficit. Annual 
control within four years with magnetic resonance 
tomography did not reveal any relapse of the tumors. 
Prognosis 
Neurofibromas are benign tumors. However, there is a 
risk of malignant transformation in PNF, leading to 
malignant peripheral nerve sheath tumors. 
Cytogenetics 
Note: Neurofibromas are benign and usually do not 
have gross chromosomal abnormality beside allelic loss 
of chromosome 17. 
Genes involved and Proteins 
NF1 
Location: 17q11.2 
Note: The direct genetic cause for neurofibromas is the 
bi-allelic inactivation of the tumor suppressor gene 
NF1. The NF1 gene is located on 17q11.2. 
DNA/RNA 
It encompasses 335 kb genomic DNA, consists of 60 
exons, and gives rise to an 11-13-kb transcript. 
Protein 
The NF1 gene product, neurofibromin, has a RAS 
GTPase-activating region (GAP) and is likely involved 
in RAS-signaling pathway. 
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Germinal mutations 
The first inactivation of the NF1 gene in a 
neurofibroma is the constitutional mutation in the 
patient. Constitutional mutations are mostly minor 
lesions such as point mutations in exons and in 
conserved splicing sites, and deletions/insertions of one 
to few base pairs, mostly leading to frameshift of the 
transcript. 
Somatic mutations: 
The 2nd inactivation of the NF1 gene in neurofibromas  
is somatic and specific to each tumor which does not 
exist in non-tumor tissues of the patient. Somatic 
inactivation involves small lesions and loss of the 2nd 
NF1 allele. 
Neurofibromas are composed mainly of Schwann cells 
and fibroblasts. By selectively culturing Schwann cells 
and fibroblasts, respectively, from an neurofibroma, is 
has been demonstrated that the somatic NF1 alterations 
only exist in the former but not in the later cell type. 
These results provided genetic evidence that Schwann 
cells are the progenitor tumor cells in neurofibromas. 
Result of the chromosomal 
anomaly 
Hybride Gene 
Note: Loss of chromosome 17 leads to bi-allelic 
inactivation of the NF1 gene. 
References 
Knudson AG. Mutation and cancer: statistical study of 
retinoblastoma. Pro Natl Acad Sci USA 1971;68:820-823. 
Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, 
Wigler M, Collins F. The NF1 locus encodes a protein 
functionally related to mammalian GAP and yeast IRA proteins. 
Cell 1990;63(4):851-859. 
Cawthon R, Weiss R, Xu G, Viskochil D, Vulver M, Stevens J, 
Robertson M, Dunn D, Gesteland R, O Connell P, White R. A 
major segment of neurofibromatosis type 1 gene: cDNA 
sequence, genomic structure and point mutations. Cell 
1990;62:193-201. 
Viskochil D, Buchberg AM, Xu G, Stevens J, Wolff RK, Culver 
M, Carey JC, Copeland NG, Jenkins NA, White R, O Connel P. 
Deletions and translocations interrupt a cloned gene at the 
neurofibromatosis type 1 locus. Cell 1990;62:187-192. 
Colman SD, Williams CA, Wallace MR. Benign neurofibromas 
in type 1 neurofibromatosis (NF1) show somatic deletions of 
NF1 gene. Nat Genet 1995;11:90-92. 
Serra E, Puig S, Otero D, Gaona A, Kruyer H, Ars E, Estivill X, 
Lazaro C. Confirmation of a double-hit model for the NF1 gene 
in benign neurofibromas. Am J Hum Genet 1997;61:512-519. 
Tonsgard JH, Kwak SM, Short MP, Dachman AH. CT imaging 
in adults with neurofibromatosis-1: frequent asymptomatic 
plexiform lesions. Neurology 1998;50(6):1755-1760. 
Kluwe L, Friedrich R, Mautner VF. Loss of NF1 allele in 
Schwann cells but not in fibroblasts derived from an NF1-
associated neurofibroma. Genes Chromosomes Cancer 
1999;3:283-285. 
Serra E, Rosenbaum T, Winner U, Aledo R, Ars E, Estivill X, 
Lenard H-G, Lazaro C. Schwann cells harbor the somatic NF1 
mutation in neurofibromas: evidence of two different Schwann 
cell subpopulations. Hum Mol Genet 2000;9:3055-3064. 
Woodruff JM, Kourea HP, Louis DN, Scheithauer BW. World 
Health Organization Classification of Tumours. Pathology and 
Genetics of Tumours of the Nervous System. Neurofibroma. P 
Kleihues, WK Cavenee (Eds.), IARC Press, Lyon, 2000;167-
168. 
Cichowski K, Jacks T. NF1 tumor suppressor gene function: 
narrowing the GAP. Cell 2001;104(4):593-604. (Review). 
McLaughlin ME, Jacks T. Progesterone receptor expression in 
neurofibromas. Cancer Res 2003;63(4):752-755. 
Upadhyaya M, Han S, Consoli C, Majounie E, Horan M, 
Thomas NS, Potts C, Griffiths S, Ruggieri M, von Deimling A, 
Cooper DN. Characterization of the somatic mutational 
spectrum of the neurofibromatosis type 1 (NF1) gene in 
neurofibromatosis patients with benign and malignant tumors. 
Hum Mutat 2004;23:134-146. 
Friedrich RE, Schmelzle R, Hartmann M, Mautner VF. Subtotal 
and total resection of superficial plexiform neurofibromas of 
face and neck: four case reports. J Craniomaxillofac Surg 
2005;33:55-60. 
Friedrich RE, Schmelzle R, Hartmann M, Funsterer C, Mautner 
VF. Resection of small plexiform neurofibromas in 
neurofibromatosis type 1 children. World J Surg Oncol 
2005;3:6. 
Lammert M, Friedman JM, Kluwe L, Mautner VF. Prevalence 
of neurofibromatosis 1 in German children at elementary 
school enrollment. Arch Dermatol 2005;141(1):71-74. 
Lammert M, Mautner VF, Kluwe L. Do hormonal contraceptives 
stimulate growth of neurofibromas? A survey on 59 NF1 
patients. BMC Cancer 2005;5:16. 
Mautner VF, Hartmann M, Kluwe L, Friedrich RE, Funsterer C. 
MRI growth patterns of plexiform neurofibromas in patients 
with neurofibromatosis type 1. Neuroradiology 2006;48(3):160-
165. 
This article should be referenced as such: 
Kluwe L, Hagel C, Mautner V. Nervous system: Neurofibroma. 
Atlas Genet Cytogenet Oncol Haematol.2007;11(4):344-347.  
 
 
